Ruxolitinib as GVHD Prophylaxis in AA Patients
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Study ID
- NCT05914714
- Phase
- PHASE2
- Status
- Unknown
Conditions
- The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib 5 MG BID Oral Tablet — DRUGruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
Study Details
Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation. The cumulative incidence of aGVHD within 6 months after HSCT will be the primary observation item.
Key Dates
- Start date
- Jul 1, 2023
- Status verified
- May 2023
- Primary completion
- May 1, 2025
- Completion
- May 1, 2025
Study Design
- Enrollment
- 46 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: treatment arm
Primary Outcome Measure
cumulative incidence of aGVHD [ Time Frame: 6 months post-HSCT ]